Articles

PerkinElmer acquires Avalon Instruments for Raman

Acquisition will broaden PerkinElmer’s molecular spectroscopy product portfolio with a Raman spectrometer line.
Written byLisa Espenschade
| 2 min read

BOSTON—PerkinElmer Inc.'s, acquisition of Avalon Instruments Limited, based in Belfast, Northern Ireland, will broaden PerkinElmer's molecular spectroscopy product portfolio with a Raman spectrom­eter line.

Simon Wells, molecular spectroscopy business manager, life and analytical scienc­es, at PerkinElmer says Avalon's dispersive Raman products complement PerkinElmer's existing ultraviolet and infrared spectrome­try offerings. "From a technical point of view, this is a very strong fit with PerkinElmer's current technology and product portfolio." Under the acquisition, which was finalized on September 1, PerkinElmer acquired all Avalon's intellectual property and products, including Raman-based microscopes and spectrometers. Financial terms of the deal were not released.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Published In

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Illustration of multiple three-dimensional patient-derived organoids suspended against a dark blue background, representing tumor models used in precision oncology research.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
Illustration of multiple three-dimensional patient-derived organoids suspended against a dark blue background, representing tumor models used in precision oncology research.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
3D illustration of a membrane protein embedded within a lipid nanodisc, representing a native-like environment used for membrane protein stabilization and characterization.
Mass photometry supports membrane protein characterization by providing rapid insights into sample composition, purity, and molecular assembly.
Drug Discovery News December 2025 Issue
Latest IssueVolume 21 • Issue 4 • December 2025

December 2025

December 2025 Issue

Explore this issue